Compare ELME & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELME | VYGR |
|---|---|---|
| Founded | 1960 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.2M | 194.0M |
| IPO Year | 1994 | 2015 |
| Metric | ELME | VYGR |
|---|---|---|
| Price | $2.09 | $4.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $12.67 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 1.1M | 724.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 33.64% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $206,360,000.00 | $10,135,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $71.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.10 | $2.65 |
| 52 Week High | $17.68 | $5.55 |
| Indicator | ELME | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 12.30 | 69.35 |
| Support Level | $2.10 | $3.84 |
| Resistance Level | $2.26 | N/A |
| Average True Range (ATR) | 0.04 | 0.29 |
| MACD | 0.22 | 0.13 |
| Stochastic Oscillator | 13.64 | 84.81 |
Elme Communities is a real estate investment trust engaged in owning and operating properties in the greater Washington DC metropolitan area. The company's real estate portfolio is comprised of office, retail, and multifamily properties located near transportation nodes. Washington REIT derives nearly all of its income in the form of rental revenue from tenants organized into long-term leases. The company's office assets contribute the majority of this income, while the rest is split fairly evenly between its retail and multifamily locations. Washington REIT's tenants are banking, consulting, law, and financial services firms.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.